Shan Ahmed Khan, Author at TechStock²

Life360 (ASX:360, Nasdaq:LIF) Stock on 8 December 2025: Q3 Beat, Nativo Deal, Sell‑Off and 2026 Forecasts

8 December 2025 – Life360, Inc., the family safety and location‑sharing platform behind the Life360 app and Tile trackers, is having another volatile day on the markets despite reporting record third‑quarter results and announcing a major ad‑tech acquisition. On the

8 December 2025

Bloom Energy (BE) Stock on December 8, 2025: AI Data Center Powerhouse or Overheated Trade?

Bloom Energy Corporation (NYSE: BE) has turned into one of 2025’s loudest stock stories. The fuel‑cell maker riding the AI data‑center boom has delivered a life‑changing move for early believers, with the share price up around 1,100% over the past

8 December 2025

AI Technology · Growth Stocks · Market Trends · NYSE:BE · Renewable Energy · Stock Analysis

Fluence Energy (FLNC) Stock Today: Downgrades Hit High-Flying Battery Storage Play – Latest News, Price Targets and Forecasts

On December 8, 2025, Fluence Energy, Inc. (NASDAQ: FLNC) is giving investors a live lesson in volatility. After a huge rally over the past two weeks, the grid‑scale battery and software specialist is trading around $22–23 per share, down roughly

8 December 2025

Battery Technology · Energy Sector · Financial News · Investment Analysis · NASDAQ:FLNC · Stock Market

Marvell Technology (MRVL) Stock Tumbles on Amazon and Microsoft Fears as AI Growth Story Gets Re‑Priced

Updated: December 8, 2025 Marvell Technology, Inc. (NASDAQ: MRVL) just got a harsh reminder that being an “AI infrastructure winner” doesn’t make you invincible. On Monday, December 8, Marvell stock fell sharply after a high‑profile analyst downgrade tied to possible

8 December 2025

Artificial Intelligence · Financial News · Investment Analysis · NASDAQ:MRVL · Stock Market · Technology

Air Products Stock Plunges to 52‑Week Low on Yara Hydrogen Deal – What It Means for APD Investors Now

Air Products and Chemicals, Inc. (NYSE: APD) just had a rough session.On December 8, 2025, the stock dropped roughly 9–10%, hit a new 52‑week low around $235–236, and briefly became the worst performer in the S&P 500 after the company

8 December 2025

Company News · Financial Analysis · Hydrogen Economy · Investing · NYSE:APD · Stock Market

Legend Biotech (LEGN) Stock Hits 52‑Week Low After UBS Cut: December 8, 2025 News, Outlook and Forecast

Legend Biotech Corp. (NASDAQ: LEGN) shares are under heavy pressure on December 8, 2025, trading in the mid‑$20s and touching a new 52‑week low around $25.66 during the session. The slide comes despite strong clinical momentum for its flagship CAR‑T

8 December 2025

Biotech News · Company Updates · Financial Forecasts · Investment Analysis · NASDAQ:LEGN · Stock Market

Warby Parker (WRBY) Stock Soars on Google AI Glasses Timeline: Price Action, Earnings and 2026 Forecasts as of December 8, 2025

Updated December 8, 2025 Warby Parker Inc. (NYSE: WRBY) is suddenly trading like an AI story, not just an eyewear retailer. Shares jumped around 15% on Monday, December 8, 2025, with the stock recently changing hands near $21.51, after fresh

8 December 2025

Financial News · Investing · Market Analysis · NYSE:WRBY · Stocks · Technology

Arrowhead Pharmaceuticals (ARWR) Soars to Fresh Highs on Alzheimer’s Trial and FDA Breakthrough Wins

Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) is finishing 2025 with the kind of momentum small-molecule biotechs daydream about. On 8 December 2025, the RNA interference (RNAi) specialist climbed to a new 52‑week high near $69 per share after the company announced

8 December 2025

Biotech Stocks · Clinical Trials · FDA Approvals · NASDAQ:ARWR · Pharmaceutical News · Stock Performance

Nurix Therapeutics (NRIX) Stock Soars on ASH 2025 Trial Data: Latest News, Analyst Forecasts and Outlook as of December 8, 2025

Nurix Therapeutics, Inc. (NASDAQ: NRIX) is back in the spotlight. On December 8, 2025, the biotech stock surged roughly 20% intraday after the company released new Phase 1 data for its Bruton’s tyrosine kinase (BTK) degrader bexobrutideg (NX‑5948) in blood

8 December 2025

Biotech · Clinical Trials · Investment Analysis · Pharmaceuticals · Stock Market

Carvana (CVNA) Soars on S&P 500 Inclusion: Latest News, Stock Forecast and Analysis as of December 8, 2025

Carvana Co. (NYSE: CVNA) is back in the spotlight. On Monday, December 8, 2025, the online used-car retailer’s shares surged again after S&P Dow Jones Indices confirmed that Carvana will join the benchmark S&P 500 index on December 22, 2025.

8 December 2025

Company Updates · Financial News · Investment Analysis · NYSE:CVNA · S&P 500 · Stock Market

Kymera Therapeutics (KYMR) Stock Soars on KT‑621 Eczema Data: What December 8, 2025 Means for Investors

Kymera Therapeutics, Inc. (NASDAQ: KYMR) delivered one of the biggest biotech moves on Wall Street today. On Monday, December 8, 2025, Kymera stock surged more than 40% intraday, trading around $96 late in the session after touching an intraday high

8 December 2025

Biotech News · Eczema Research · Investing · NASDAQ:KYMR · Pharmaceutical Industry · Stock Market

Wave Life Sciences (WVE) Stock Explodes on Obesity Drug Breakthrough – What the New Data and Wall Street Forecasts Signal

Published: December 8, 2025 WVE stock more than doubles on massive volume Wave Life Sciences Ltd. (NASDAQ: WVE) staged a spectacular rally on Monday after unveiling positive interim data from its Phase 1 INLIGHT trial for obesity drug candidate WVE‑007.

8 December 2025

Biotechnology · Investment · NASDAQ:WVE · Obesity · Stocks · Wall Street